A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2011
10/13/2011	WO2011043630A3 Composition for preventing and treating obesity diseases containing highly water-soluble 2-hydroxypropyl-β-cyclodextrin as active ingredient
10/13/2011	WO2011038086A3 Indolizine inhibitors of 5-lipoxygenase
10/13/2011	WO2011037411A3 Composition comprising s-allyl-l-cysteine as active ingredient for preventing or treating gastrointestinal disorders
10/13/2011	WO2011034951A3 Assisted enzyme replacement therapy
10/13/2011	WO2011031890A4 Cancer stem cell-targeted and drug resistant cancer therapy
10/13/2011	WO2011029948A3 Transdermal therapeutic system for administering fentanyl or an analogue thereof
10/13/2011	WO2011009903A3 Material system comprising endoperoxide adapting to decomposition, and applications
10/13/2011	WO2010146408A4 Nanoparticulate olmesartan medoxomil compositions, process for the preparation thereof and pharmaceutical compositions containing them
10/13/2011	WO2010132765A9 Antibacterial aminoglycoside analogs
10/13/2011	WO2010124198A9 Agglomerate formulations useful in dry powder inhalers
10/13/2011	WO2010107435A8 A novel alpha-(n-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
10/13/2011	WO2010091822A3 N-hydroxylated amidine-, guanidine- and/or aminohydrazone-type prodrugs for application on the skin
10/13/2011	WO2007067036A3 New use of carbonic anhydrase inhibitors
10/13/2011	US20110251677 Coating Designs For The Tailored Release Of Dual Drugs From Polymeric Coatings
10/13/2011	US20110251566 Apparatuses, methods, and compositions for the treatment and prophylaxis of chronic wounds
10/13/2011	US20110251290 Treatment of hepatic encephalopathy and liver cirrhosis
10/13/2011	US20110251289 New compounds for the treatment of cancer
10/13/2011	US20110251288 Process for the preparation of enantiomerically pure amines
10/13/2011	US20110251287 Hci polymorphs of 3-((2-(dimethylamino)methyl (cyclohex-1-yl))phenol
10/13/2011	US20110251286 Crystalline salts and/or co-crystals of O-desmethyltramadol
10/13/2011	US20110251284 Halo active aromatic sulfonamide organic compounds and uses therefor
10/13/2011	US20110251283 1-amino-alkylcyclohexane derivatives for the treatment of mast cell mediated diseases
10/13/2011	US20110251282 Liquid compositions of calcium acetate
10/13/2011	US20110251281 Composite Material Comprising High-Molecular-Weight Matrix and Low-Molecular-Weight Organic Compound and Process For Producing Same
10/13/2011	US20110251280 Stable Aqueous Compositions Comprising Amide-Protected Bioactive Creatine Species and Uses Thereof
10/13/2011	US20110251279 Composition of Amino Acids for Sublingual Applying for Enhanced Skin Integument Repigmentation in Vitiligo and Method of its Administration
10/13/2011	US20110251278 Microalgae extract containing omega 3-polyunsaturated fatty acids and method for extracting oil from micro-organisms
10/13/2011	US20110251276 Biological oil composition, formulations comprising the oil composition, and use thereof to prevent or treat cardiovascular disease
10/13/2011	US20110251275 Omega-3 fatty acids for reduction of lp-pla2 levels
10/13/2011	US20110251274 Natural Vitamin E Compositions with Superior Antioxidant Potency
10/13/2011	US20110251272 Methods and compositions for predicting drug responses
10/13/2011	US20110251270 Compounds and methods for repelling blood-feeding arthropods and deterring their landing and feeding
10/13/2011	US20110251269 Preparation method of polymeric micelles composition containing a poorly water-soluble drug
10/13/2011	US20110251268 Antioxidant-containing food composition for use in inhibiting histamine pathways in companion animals
10/13/2011	US20110251267 Methods of using polynucleotides encoding truncated glial cell line-derived neurotrophic factor
10/13/2011	US20110251266 Aptamer for ngf and use thereof
10/13/2011	US20110251264 Transcription factor decoys
10/13/2011	US20110251263 RNAi Modulation of the BCR-ABL Fusion Gene and Uses Thereof
10/13/2011	US20110251262 Compositions And Methods For Inhibiting Expression Of An RNA From West Nile Virus
10/13/2011	US20110251261 Compositions and methods for inhibition of nucleic acids function
10/13/2011	US20110251260 NOVEL siRNAS AND METHODS OF USE THEREOF
10/13/2011	US20110251259 Compositions and methods for inhibiting expression of cd274/pd-l1 gene
10/13/2011	US20110251258 Rnai constructs and uses thereof
10/13/2011	US20110251257 Methods and compositions for treating neurological disease
10/13/2011	US20110251256 Use of trim72 as a target for muscle and heart enhancer
10/13/2011	US20110251255 Methods and Compositions for Inhibiting the Proliferation of Cancer Cells
10/13/2011	US20110251254 Novel salt of tegaserod
10/13/2011	US20110251253 Solid forms of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide
10/13/2011	US20110251252 Biomarkers for mdm2 inhibitors for use in treating disease
10/13/2011	US20110251251 Polymorph ii of an antifungal compound
10/13/2011	US20110251250 Use of dimiracetam in the treatment of chronic pain
10/13/2011	US20110251249 Dual-acting antihypertensive agents
10/13/2011	US20110251248 Glucagon receptor antagonist compounds
10/13/2011	US20110251247 Substituted isoxazoline derivatives
10/13/2011	US20110251246 Small molecule inhibitors of muc1 and methods of identifying the same
10/13/2011	US20110251245 Solid pharmaceutical composition comprising amlodipine and losartan
10/13/2011	US20110251244 Oral Dosage Form Containing A PDE 4 Inhibitor As An Active Ingredient And Polyvinylpyrrolidone As Excipient
10/13/2011	US20110251243 Method and Kit for Assessing a Patient's Genetic Information, Lifestyle and Environment Conditions, and Providing a Tailored Therapeutic Regime
10/13/2011	US20110251242 Photostabilization of resveratrol with alkoxycrylene compounds
10/13/2011	US20110251240 Dosing Regimen of Flavopiridol for Treating Cancer
10/13/2011	US20110251239 Combination therapy for the treatment of dementia
10/13/2011	US20110251238 Ppar agonist compositions and methods of use
10/13/2011	US20110251237 2,5-Disubstituted Piperidine Orexin Receptor Antagonists
10/13/2011	US20110251236 Galactokinase inhibitors
10/13/2011	US20110251235 Stable laquinimod preparations
10/13/2011	US20110251234 Mesylate salt of 5-(2--1-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one as agonist of the beta2 adrenergic receptor
10/13/2011	US20110251233 Formulation for the buccal transmucosal administration of setrons
10/13/2011	US20110251232 Modified release compositions comprising tacrolimus
10/13/2011	US20110251231 Modified release compositions comprising tacrolimus
10/13/2011	US20110251230 Therapeutics for neurological disorders
10/13/2011	US20110251229 (+)-opioids and methods of use
10/13/2011	US20110251228 Nalmefene hydrochloride dihydrate
10/13/2011	US20110251227 Analgesic agents
10/13/2011	US20110251226 Cyclohexylamin isoquinolone derivatives
10/13/2011	US20110251225 Substituted tetrahydropyran spiro pyrrolidinone and piperidinone, preparation and therapeutic use thereof
10/13/2011	US20110251224 Spiro-oxindole compounds and their uses as therapeutic agents
10/13/2011	US20110251223 CGRP Receptor Antagonists
10/13/2011	US20110251222 Sulfone-substituted anilinopyrimidine derivatives as cdk inhibitors, the production thereof, and use as a medicine
10/13/2011	US20110251221 Pyrimidinylpiperidinyloxypyridinone analogues as gpr119 modulators
10/13/2011	US20110251220 Pharmaceutical compositions comprising gamma secretase modulators
10/13/2011	US20110251219 Treatment for glomerulonephritis with 2-[4-(7-ethyl-5h-pyrrolo[2,3-b]pyrazin-6-yl)phenyl]propan-2-ol
10/13/2011	US20110251218 Novel compounds
10/13/2011	US20110251217 Substituted purinyl-pyrazol derivatives and their use as potassium channel modulators
10/13/2011	US20110251216 Compositions and methods for inhibiting ezh2
10/13/2011	US20110251215 Macrocyclic compounds and their use as kinase inhibitors
10/13/2011	US20110251214 Monohydrate of pardoprunox
10/13/2011	US20110251212 Piperazine derivatives
10/13/2011	US20110251211 Methods of using substituted isoxazolo pyridinones as dissociated glucocorticoids
10/13/2011	US20110251210 Modified chloroquines with single ring moiety or fused ring moiety
10/13/2011	US20110251209 Compounds for treating parasitic disease
10/13/2011	US20110251208 Phosphodiesterase type iii (pde iii) inhibitors or ca2+-sensitizing agents for the treatment of hypertrophic cardiomyopathy
10/13/2011	US20110251207 Biaryl-spiroaminooxazoline analogues as alpha 2c adrenergic receptor modulators
10/13/2011	US20110251206 Squaramide derivatives as CXCR2 antagonist
10/13/2011	US20110251205 Squaramide derivatives as cxcr2 antagonist
10/13/2011	US20110251204 Modulators of G Protein-Coupled Receptor 88
10/13/2011	US20110251203 Use of pkc inhibitors in diabetic complications
10/13/2011	US20110251202 1,3-Dihydro-imidazo[4,5-c]quinolin-2-ones as Lipid Kinase Inhibitors
10/13/2011	US20110251201 Sustained release intraocular implants and methods for preventing retinal dysfunction
10/13/2011	US20110251200 Aryl guanidine f1f0-atpase inhibitors and related methods
10/13/2011	US20110251199 Nitrogen-containing bicyclic heteroaryl compounds and methods of use

1 ... 1523 1524 1525 1526 1527 1528 1529 1530 1531 1532 1533 1534 1535 1536 1537 1538 1539 1540 1541 1542 1543 ... 7860